Work

Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.3520

Authors: Christine Megerdichian Parseghian, Eduardo Vilar Sanchez, Ryan Sun, Madhulika Eluri, Van K. Morris, Benny Johnson, Maria Pia Morelli, Michael J. Overman, Jason Willis, Ryan Huey, Kanwal Pratap Singh Raghav, Arvind Dasari, Bryan K. Kee, Robert A. Wolff, John Paul Y.C. Shen, Scott Kopetz

Institutions: The University of Texas MD Anderson Cancer Center, National Cancer Institute, University of California San Diego, Moores Cancer Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4286297039

Cites:

Cited by: 9

Related to: 10